Biomark Diagnostics Inc. (FRA:20B)

Market Cap	29.00M +190.1%
Revenue (ttm)	75.52K -21.9%
Net Income	-1.01M
EPS	-0.01
Shares Out	105.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	237
Open	0.2780
Previous Close	0.2860
Day's Range	0.2780 - 0.2780
52-Week Range	0.0985 - 0.3200
Beta	-0.07
RSI	50.47
Earnings Date	Feb 26, 2026

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 20B

Financial Performance

In fiscal year 2025, Biomark Diagnostics's revenue was 154,216, a decrease of -5.52% compared to the previous year's 163,220. Losses were -1.93 million, 35.0% more than in 2024.

Financial numbers in CAD